EL7.AI पर प्रदान की गई जानकारी केवल शैक्षिक और सूचनात्मक उद्देश्यों के लिए है और यह वित्तीय सलाह नहीं है।
EL7.AI पर प्रदान की गई जानकारी केवल शैक्षिक और सूचनात्मक उद्देश्यों के लिए है और यह वित्तीय सलाह नहीं है।
OS Therapies (OSTX) announced that its immunotherapy candidate, OST-HER2, has been granted the Advanced Therapy Medicinal Product (ATMP) designation by the European Medicines Agency (EMA). The designation, recommended by the Committee for Advanced Therapies (CAT), is specifically aimed at treating pulmonary recurrence in patients with resected osteosarcoma. This regulatory milestone provides the company with an accelerated pathway toward Conditional Marketing Authorisation (CMA) within the European Union. Additionally, as a small and medium-sized enterprise (SME), OS Therapies will benefit from reduced regulatory fees and enhanced scientific guidance. This development is a significant step forward for the biotech firm, potentially shortening the timeline and lowering the costs for market entry. While this designation is not a final approval, it validates the therapeutic potential of OST-HER2 in addressing rare and aggressive bone cancers.
इस कंटेंट को एक्सेस करने के लिए मुफ्त साइन अप करें
मुफ्त अकाउंट बनाएं